Washington Manual of Medical Therapeutics
Cyclic Lipopeptide
To view the entire topic, please log in or purchase a subscription.
The Washington Manual is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:
-- The first section of this topic is shown below --
Treatment
Daptomycin (4 mg/kg IV q24h for skin and skin structure infections; 6–12 mg/kg IV q24h for bloodstream infections) is the only FDA-approved cyclic lipopeptide. The drug exhibits rapid bactericidal activity against a wide variety of gram-positive bacteria, including enterococci, staphylococci, and streptococci. Daptomycin is FDA-approved for treatment of skin/soft tissue infections as well as S. aureus bacteremia and right-sided endocarditis. The drug should not be used to treat lung infections as activity is decreased in the presence of pulmonary surfactant. Nonsusceptibility to daptomycin can develop during treatment, making it imperative that susceptibility of isolates be verified.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Treatment
Daptomycin (4 mg/kg IV q24h for skin and skin structure infections; 6–12 mg/kg IV q24h for bloodstream infections) is the only FDA-approved cyclic lipopeptide. The drug exhibits rapid bactericidal activity against a wide variety of gram-positive bacteria, including enterococci, staphylococci, and streptococci. Daptomycin is FDA-approved for treatment of skin/soft tissue infections as well as S. aureus bacteremia and right-sided endocarditis. The drug should not be used to treat lung infections as activity is decreased in the presence of pulmonary surfactant. Nonsusceptibility to daptomycin can develop during treatment, making it imperative that susceptibility of isolates be verified.
There's more to see -- the rest of this topic is available only to subscribers.
